Alyeska Investment Group’s AC Immune ACIU Stock Holding History

Alyeska Investment Group’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-85,000	Closed	-$1.4M	–	464
2016 Q3	$1.4M	Buy	+85,000	New	+$1.47M	0.01%	402

Other funds holding ACIU

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Alyeska Investment Group's ACIU Position: Q4 2016 in Review

Alyeska Investment Group sold out of AC Immune (ACIU) in Q4 2016, closing a stake of 85,000 shares — an estimated $1.4M sold.

Alyeska Investment Group first reported a position in ACIU in Q3 2016 and held it in 1 quarter. The position peaked at $1.4M in Q3 2016. 19 funds tracked by Wall St. Rank hold ACIU as of Q4 2016.

Alyeska Investment Group reported no remaining AC Immune position as of Q4 2016 after selling out during the quarter.
Alyeska Investment Group sold 85,000 AC Immune shares in Q4 2016, an estimated $1.4M.
Alyeska Investment Group first reported a position in AC Immune in Q3 2016 and held it in 1 quarter.
Alyeska Investment Group's AC Immune position peaked at $1.4M in Q3 2016.
19 funds tracked by Wall St. Rank held AC Immune as of Q4 2016.

Based on Alyeska Investment Group's 13F filing for Q4 2016, filed 14 Feb 2017.